OP0130 Mepolizumab for the Treatment of Patients With Eosinophilic Granulomatosis With Polyangiitis: A Phase Iii Randomised, Placebo-Controlled Trial

doi 10.1136/annrheumdis-2017-eular.5610
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Urine Eosinophil-Derived Neurotoxin Declines Following Mepolizumab Treatment in Subjects With Eosinophilic Granulomatosis With Polyangiitis

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Pharmacogenetic Investigation of Efficacy Response to Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

Rheumatology International
RheumatologyAllergyImmunology
2020English

Eosinophilic Granulomatosis With Polyangiitis - Toward Personalized Treatment

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2017English

Familial Eosinophilic Granulomatosis With Polyangiitis

Open Journal of Rheumatology and Autoimmune Diseases
2017English

A Case of Eosinophilic Granulomatosis With Polyangiitis

The Medicine Forum
2018English

Eosinophilic Granulomatosis With Polyangiitis: Diagnostic Dilemmas

Internal Medicine
2018English

ANCA-Negative Eosinophilic Granulomatosis With Polyangiitis

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2016English

Eosinophilic Granulomatosis With Polyangiitis: An Overview

Frontiers in Immunology
AllergyImmunology
2014English

A Pilot Randomised Clinical Trial of Mepolizumab in COPD With Eosinophilic Bronchitis

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy